Rayaldee (calcifediol) — Point32Health
secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels < 30 ng/mL
Initial criteria
- Documented diagnosis of secondary hyperparathyroidism
- Patient age ≥ 18 years
- Patient has stage 3 or 4 chronic kidney disease
- Patient is not on dialysis
- Total serum 25-hydroxyvitamin D level < 30 ng/mL prior to initiating therapy
- Serum calcium level < 9.8 mg/dL prior to initiating therapy
- Patient has tried and failed therapy with OR there is clinical rationale to avoid use with TWO alternative vitamin D products such as: Nutritional Vitamin D supplements (e.g. cholecalciferol or ergocalciferol) AND/OR Vitamin D analogs (e.g. calcitriol [Rocaltrol], doxercalciferol [Hectorol], or paricalcitol [Zemplar])